Detection of Anticancer Drug-Induced Cardiotoxicity Using VCAM1-Targeted Nanoprobes

Humayra Afrin1,2, Md Nurul Huda1,2, Tamanna Islam1,2

  • 1Environmental Science and Engineering, University of Texas at El Paso, El Paso, Texas 79965, United States.

Insights

This study developed a novel fluorescent nanoprobe to detect chemotherapy-induced heart damage early. The probe targets overexpressed VCAM1 in inflamed cardiac tissue, showing promise for monitoring cardiotoxicity.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cardiology

Background:

  • Chemotherapy, particularly doxorubicin (DOX), often causes cardiotoxicity, increasing mortality and reducing quality of life.
  • Current methods lack feasibility for early detection and monitoring of chemotherapy-induced cardiac damage.
  • Vascular cell adhesion molecule 1 (VCAM1) is overexpressed in cardiac tissue due to inflammation from DOX treatment.

Purpose of the Study:

  • To develop a VCAM1-targeted fluorescent nanoprobe for early detection and imaging of chemotherapy-induced cardiotoxicity.
  • To visualize and quantify the accumulation of the nanoprobe in cardiac tissue affected by DOX treatment.

Main Methods:

  • Synthesized poly(lactic-co-glycolic acid) (PLGA) nanoparticles functionalized with a VCAM1-targeting peptide and rhodamine B (PLGA-VCAM1-RhB).
  • Evaluated selective binding and accumulation of PLGA-VCAM1-RhB in DOX-treated human cardiomyocyte cells (HCMs) in vitro.
  • Administered PLGA-VCAM1-RhB and control PLGA-RhB to DOX-treated and untreated animals in vivo for fluorescence imaging.

Main Results:

  • PLGA-VCAM1-RhB showed selective binding and higher accumulation in DOX-treated HCMs compared to untreated cells.
  • In vivo imaging revealed significantly higher fluorescent signal (48.62% ± 12.79%) in the hearts of DOX-treated animals using PLGA-VCAM1-RhB compared to controls (10.61% ± 4.90%).
  • Quantified fluorescence intensity in homogenized cardiac tissue was 156% higher in the PLGA-VCAM1-RhB group from DOX-treated animals compared to healthy controls.

Conclusions:

  • The VCAM1-targeted fluorescent nanoprobe (PLGA-VCAM1-RhB) effectively targets and binds to inflamed cardiac cells.
  • This nanoprobe demonstrates significant potential for early-stage detection and visualization of doxorubicin-induced cardiotoxicity.
  • The developed technology offers a promising tool for monitoring heart damage in patients undergoing chemotherapy.

Related Concept Videos